The Methylation Analysis of Mir-210 in NSCLC Patients

Masoumeh Masrouri, Sajad Nooshin, Arash Matin Ahmadi, Roya Zare zadeh, Mojtaba Mohammadnejad pahmadani, Morteza Karimipoor

Abstract


Background: Because of the importance of lung cancer worldwide, as well as the deaths from it. So far, various studies have been conducted on this cancer. Epigenetic changes are one of the factors contributing to lung cancer that the most important of these changes are DNA methylation. Various biomarkers such as microRNAs can be used to detect cancer. In addition, many studies have been performed on the relationship between cancer and microRNAs. In this study, the methylation status of mir-210 was investigated in NSCLC tissues.

Method: The methylation status of mir-210 was checked in 30 patients with NSCLC and 30 adjacent normal tissues using the MS-PCR method.

Results: This paper reported that there was no significant difference between methylation level of tumor samples and adjacent normal samples. so that all of the normal samples were in methylated state and only 4 (13.33%) cases of tumor samples were in a unmethylated state (P>0.05). The results obtained from our study confirmed that hypomethylation and therefore overexpression of mir-210 didn’t occur in early stages of non-small cell lung cancer.


Keywords


Lung Cancer; Non-Small Cell Lung Cancer (NSCLC); Mir-210; MS-PCR Method.

Full Text:

PDF

References


Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500.

Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56-63.

Belot A, Velten M, Grosclaude P, Bossard N, Launoy G, Remontet L, et al. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005: Institut de veille sanitaire Saint-Maurice (France); 2008.

Wang F, Mishina S, Takai S, Le TK, Ochi K, Funato K, et al. Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study. Clinical therapeutics. 2017;39(6):1146-60.

Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung cancer. 2007;57(3):253-60.

Lu W. Effects of FUX on gemcitabine sensitivity in lung cancer cells: Auckland University of Technology; 2015.

Broaddus VC, Mason RC, Ernst JD, King TE, Lazarus SC, Murray JF, et al. Murray & Nadel's Textbook of Respiratory Medicine E-Book: Elsevier Health Sciences; 2015.

Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS medicine. 2008;5(9):e185.

Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. New England Journal of Medicine. 2008;358(11):1118-28.

Yang AS, Doshi KD, Choi S-W, Mason JB, Mannari RK, Gharybian V, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer research. 2006;66(10):5495-503.

Kota SK, Balasubramanian S. Cancer therapy via modulation of micro RNA levels: a promising future. Drug discovery today. 2010;15(17-18):733-40.

Xiong L, Wang F, Huang X, Liu Zh, Zhao T, Wu Ly, et al. DNA demethylation regulates the expression of miR‐210 in neural progenitor cells subjected to hypoxia. The FEBS journal. 2012;279(23):4318-26.

Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, et al. Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014;83(2):272-8.

Kiga K, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, et al. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nature communications. 2014;5:4497.

Puissegur M, Mazure N, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell death and differentiation. 2011;18(3):465.

Huang X, Le Q-T, Giaccia AJ. MiR-210–micromanager of the hypoxia pathway. Trends in molecular medicine. 2010;16(5):230-7.

Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer research. 2009;69(3):1221-9.

Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis. 2005;26(9):1481-7.

Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507(2):135-8.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Masoumeh Masrouri

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.